Dominick Pierre-Jacques

Dominick Pierre-Jacques

Auto-generated profile, based on publicly available information

Dominick Pierre-Jacques

Department of Chemistry, University of Illinois Chicago, Chicago, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
YCYat Ho Chan
Yat Ho Chan
KPKoralege Pathmasiri
Koralege Pathmasiri
DPDominick Pierre-Jacques
Dominick Pierre-Jacques
MHMaddison C. Hibbard
Maddison C. Hibbard
NTNannan Tao
Nannan Tao
RGRuixuan Gao
Ruixuan Gao
A technique capable of label-free detection, mass spectrometry imaging (MSI) is a powerful tool for spatial investigation of native biomolecules in intact specimens. However, MSI has often been precluded from single-cell applications due to the spatial resolution limit set forth by the physical and instrumental constraints of the method. By taking advantage of the reversible interaction between the analytes and a superabsorbent hydrogel, we have developed a sample preparation and imaging workflow named Gel-Assisted Mass Spectrometry Imaging (GAMSI) to overcome the spatial resolution limits of modern mass spectrometers. With GAMSI, we show that the spatial resolution of MALDI-MSI can be enhanced ~3-6-fold to the sub-micrometer level without changing the existing mass spectrometry hardware or analysis pipeline. This approach will vastly enhance the accessibility of MSI-based spatial analysis at the cellular scale.

16 April 2025 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
ASAshutosh Sharma
Ashutosh Sharma
JZJulian Zalejski
Julian Zalejski
SBShruti Vijay Bendre
Shruti Vijay Bendre
SKSimona Kavrokova
Simona Kavrokova
HHHale Siir Hasdemir
Hale Siir Hasdemir
WCWonhwa Cho
Wonhwa Cho

30 March 2026 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
AMAvani V Mylvara
Avani V Mylvara
AGAlana L Gibson
Alana L Gibson
TGTansy Gu
Tansy Gu
CDCristin Davidson
Cristin Davidson
AIArturo A Incao
Arturo A Incao
WPWilliam J. Pavan
William J. Pavan
Niemann–Pick disease, type C1 (NPC1), is a rare, fatal neurodegenerative disorder caused by pathological variants in NPC1 , which encodes a lysosomal cholesterol transporter. FDA-approved treatments are limited and do not target the underlying genetic defect. Both systemic and central nervous system delivery of AAV9-h NPC1 have shown significant disease amelioration in NPC1 murine models. To assess the impact of dose in null Npc1 m1N/m1N mice, we systemically administered three different doses of AAV9-h NPC1 at 4 wk old. Then, to assess the impact of age, we administered the medium dose before phenotypic onset or at early or late stage of disease progression (4, 6, or 8 wk old, respectively). Higher vector doses and earlier treatment were associated with significantly increased lifespan, slower disease progression, and enhanced central nervous system transduction. In Npc1 I1061T/I1061T mice, a model recapitulating a common human hypomorphic variant, similar benefits ensued. Our findings help define dose ranges, treatment ages, and efficacy in hypomorphic models of NPC1 deficiency and suggest that higher doses of AAV9-h NPC1 in presymptomatic disease states are likely to yield better outcomes in NPC1 individuals.